Dr. Ren\u00e9 Maltais has been working as a medicinal chemist for over twenty years on the development of innovative bioactive molecules targeting major diseases such as cancer, endometriosis, and specific chronic and acute inflammatory diseases. He stands as a co-inventor of the anticancer molecule RM-581, which led to the creation of Neolys Pharma. He is also behind the design of PBRM, a 17 beta-HSD1 inhibitor developed for the treatment of endometriosis. This molecule, the discovery of which led to a partnership with Madrid-based pharmaceutical company Insud Pharma, is about to start clinical trials.
<\/p>\n\n\n\n
Dr.\u00a0Maltais has written and co-written over 90\u00a0papers in internationally renowned scientific journals and given over 125\u00a0presentations at local, national, and international conferences. He is listed as an inventor in 10\u00a0patent applications. He is also a cofounder of the Organic Synthesis Service, a major component of the medicinal chemistry platform at the CHU de Qu\u00e9bec. As head of this platform, Dr.\u00a0Maltais has supervised more than 80\u00a0projects involving the synthesis of molecules of interest to researchers in the Quebec scientific community and beyond. He also plays an active role in training students in the laboratory, and has been contributing to various courses at Universit\u00e9\u00a0Laval\u2019s\u00a0Faculty of Medicine. These achievements led to him winning the national award for excellence from the Fonds de recherche en Sant\u00e9 du Qu\u00e9bec in 2017.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":true},"categories":[17],"class_list":["post-579","member","type-member","status-publish","hentry","category-co-founder"],"acf":[],"yoast_head":"\n